Transactions
QOL Medical recapitalized by an investor group led by Cooper Capital
Nov. 2010
Client: QOL is a rare disease pharmaceutical company that markets Sucraid for the treatment of Congenital Sucrase-Isomaltase Disorder (CSID)
Role: Edgemont Partners acted as exclusive financial advisor to QOL Medical in its recapitalization by Cooper Capital
Location: Vero Beach, FL
Sector: Pharmaceutical Services
Lead Banker: David Blume
recapitalized by an investor group led by
